glp 1 gip dual agonist lilly Molecular Glue Eli Lilly tests GLP-1 candidate

Requires medical evaluation and approval by a licensed provider

Our findings strongly suggest the answer is yes. Primes recent real-world study found 63% of high-potency GLP-1 (Wegovy or Zepbound) users who started treatment in Q1 2024 are still taking their medication after a year

The global epidemic of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) and the high prevalence among individuals with type 2 diabetes has attracted the attention of clinicians specialising in liver disorders

SUMMARYIncretin therapy is based on the antidiabetic actions of the incretin hormone GLP-1

For patients, oral therapies promise greater convenience, improved adherence, and broader access, particularly for those reluctant to use injectables